ФРИМАН Гордан (US),ШАРП Эрлин (US),ДОРФМАН Дэвид М. (US),АХМЕД Рафи (US),БАРЬЕР Дэниел (US),УИРРИ Е. Джонсон (US)
申请号：
RU2011133335/15
公开号：
RU2011133335A
申请日:
2011.08.08
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
1. Composition for mitigating or preventing persistent infection, angioimmunoblastic lymphoma or nodular lymphoid-dominated Hodgkin's lymphoma, containing an inhibitor of the activity or expression of PD-1.2. The composition of claim 1, wherein said PD-1 activity or expression inhibitor decreases PD-L1.3 expression or activity. The composition of claim 2, wherein said PD-1 activity or expression inhibitor is an anti-PD-L1.4 antibody. The composition of claim 3, wherein said persistent infection is a human immunodeficiency virus, human T-lymphotrophic virus, herpes virus, Epstein-Barr virus or human papillomavirus. The composition of claim 3, wherein said persistent infection is a human immunodeficiency virus infection. The composition of claim 5, further comprising a vaccine. The composition of claim 6, wherein said vaccine elicits an immune response against a human immunodeficiency virus. The composition according to claim 1, prepared for implantation. The composition according to claim 1, prepared for systemic administration. The composition according to claim 1, prepared for parenteral administration. The composition of claim 1, further comprising an antiviral agent. The composition of claim 1, wherein said PD-1 inhibitor is an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-PD-L2 antibody, anti-PD-1-RNAi, anti-PD-L1-RNAi, anti- PD-L2-RNAi, anti-PD-1 antisense RNA, anti-PD-L1 antisense RNA, anti-PD-L2 antisense RNA, dominant negative protein PD-1, dominant negative protein PD-L1 or dominant negative protein PD-L2.13. The composition of claim 3, wherein said anti-PD-L1 antibody is a monoclonal antibody or a humanized monoclonal antibody.1. Композиция для смягчения или предотвращения персистирующей инфекции, ангиоиммунобластической лимфомы или нодулярной с лимфоидным преобладанием лимфомы Ходжкина, содержащая ингибитор активности или экспрессии PD-1.2. Композиция по п.1, где указанный ингибитор активности или экспрессии PD-1 понижает экспрессию или активность P
